GlassScriptPhysician profile
Marilyn Suri
NPI 1245576743
$4,535.98
in general payments reported to CMS, 2019-2025
21 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $79.09 · 2024: $1,865 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $649.61 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $470.97 | 2024-2025 | Rejoyn, Rexulti |
| Madrigal Pharmaceuticals | $425.31 | 2025 | Rezdiffra |
| Amgen INC. | $371.28 | 2024-2025 | Uplizna, Krystexxa |
| Novo Nordisk INC | $340.96 | 2024-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.52 | 2024-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $285.01 | 2024 | |
| Neurocrine Biosciences, INC. | $249.98 | 2025 | |
| Abbvie INC. | $221.98 | 2022-2025 | |
| Abiomed | $181.93 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $132.08 | 2024 | Austedo Xr |
| Optinose US, INC. | $127.18 | 2025 | |
| Amarin Pharma, INC. | $124.99 | 2024 | |
| Lilly USA, LLC | $124.46 | 2024 | Zepbound |
| Pfizer INC. | $113.25 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $112.43 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $79.09 | 2023 | Amvuttra |
| Genzyme Corporation | $76.50 | 2025 | |
| Exact Sciences Corporation | $75.64 | 2024 | Cologuard Collection Kit |
| Medivance, INC. | $28.17 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.